Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

Insights into the structures could lead to improved treatment strategies for transthyretin amyloidosis, a progressive, fatal disease in men.

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.